Concepedia

M. Ballinger

MB

Statistics

Publications

20

Citations

915

H-Index

17

Active since

1992

Affiliations

University of California, Davis(Current)

UC Davis Comprehensive Cancer Center

Samsung Medical Center

Kaiser Permanente Vallejo Medical Center

Sungkyunkwan University

M. Ballinger is an author at University of California, Davis specializing in oncology, atezolizumab therapy, and medicine.

ORCID

Publications per year

1992–2023

20

Publications

20

Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial.

Maha Hussain, Matthew Ryan Smith, C. Sweeney et al. · Journal of Clinical Oncology · 2011 · 110 citations

, , +17

Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Joachim von Pawel, Rodolfo Bordoni, Miyako Satouchi et al. · European Journal of Cancer · 2018 · 106 citations

, , +12

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

David R. Gandara, Marcin Kowanetz, Tony Mok et al. · Annals of Oncology · 2017 · 85 citations · Full text

, , +17

Activation of the anaerobic ribonucleotide reductase from Escherichia coli by S-adenosylmethionine.

Jens Harder, R. Eliasson, E Pontis et al. · Journal of Biological Chemistry · 1992 · 72 citations · Full text

, , +16

Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Fabrice Barlési, K. Park, Fortunato Ciardiello et al. · Annals of Oncology · 2016 · 71 citations · Full text

, , +4

1–5 of 20